FDA approves lisocabtagene maraleucel for relapsed or refractory mantle cell lymphoma

On May 30, 2024, the Food and Drug Administration approved lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc.) for adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have received at least two prior lines of systemic therapy, including a Bruton tyrosine kinase inhibitor (BTKi).

Leave a Comment

Your email address will not be published. Required fields are marked *